Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Omeros Corporation (NASDAQ:OMER) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $40.3333.

A number of research firms have issued reports on OMER. Weiss Ratings downgraded shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Omeros in a research report on Wednesday, June 10th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th.

Insider Activity at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the transaction, the director owned 35,067 shares in the company, valued at $407,127.87. This represents a 17.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of OMER. UBS Group AG increased its stake in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after purchasing an additional 666,357 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the last quarter. State Street Corp increased its stake in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Up 1.3%

OMER stock opened at $10.72 on Friday. Omeros has a 12-month low of $2.95 and a 12-month high of $17.65. The company has a market cap of $775.91 million, a price-to-earnings ratio of 15.31 and a beta of 2.52. The company has a 50 day moving average of $11.97 and a two-hundred day moving average of $11.88.

Omeros (NASDAQ:OMER) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. On average, research analysts anticipate that Omeros will post -0.94 EPS for the current year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.